超声引导性s骨麻醉的临床值在腔内和/或间质近距离术中用于宫颈癌的临床价值
The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer
影响因子:4.10000
分区:医学2区 Top / 妇产科学1区 肿瘤学2区
发表日期:2024 Dec
作者:
Xiaojing Yang, Chen Li, Zhen Li, Dongping Du, Jie Fu
摘要
探索宫颈癌患者的腔内和/或间质性近距离治疗中超声引导的1.骨麻醉的有效性和安全性。进行了一次回顾性分析，总共进行了103999个疗法内和/或间际猪尿的1039例，涉及220年12月7日，2020年3月21日，2024年3月7日，涉及220名患者的患者。体征，麻醉的发作时间，麻醉药的剂量，麻醉持续时间以及不良反应的发生率。对麻醉的满意度为73.8％。麻醉前后，患者心率（HR），平均动脉压（MAP），收缩压（SBP）或氧饱和度（SAO2）没有显着差异（P> 0.05）。麻醉的发作时间范围为20至35分钟，麻醉的平均剂量为20 mL，麻醉持续时间持续了30至120分钟。严重的不良反应包括2例麻醉后晕厥病例（与骨囊肿有关）。恶心的发生率为2.2％，其他不良反应的总发病率，例如呕吐，保留率，心动过缓，肛门不适和头晕的发生率不到1％。散布引导性的s骨麻醉引导性的麻醉表现出显着的优势，包括有效的麻醉，对静电的影响，速度迅速的促进，速度迅速且迅速的反应量，并迅速促进。建议在宫颈癌患者的腔内和/或间质近距离疗法中广泛应用。
Abstract
To explore the effectiveness and safety of ultrasound-guided sacral anesthesia in intracavitary and/or interstitial brachytherapy for cervical cancer patients.A retrospective analysis was conducted on a total of 1039 intracavitary and/or interstitial brachytherapy involving 220 patients in our department from December 7, 2020 to March 21, 2024. The study assessed the satisfaction with anesthesia, changes in vital signs, onset time of anesthesia, dosage of anesthetic drugs, duration of anesthesia, and incidence of adverse reactions.The rate of satisfaction with anesthesia was 73.8 %. There were no significant differences in patients' heart rate (HR), mean arterial pressure (MAP), systolic blood pressure (SBP), or oxygen saturation (SaO2) before and after anesthesia (P > 0.05). The onset time of anesthesia ranged from 20 to 35 min, the average dosage of anesthetic was 20 ml, and the duration of anesthesia lasted from 30 to 120 min. Serious adverse reactions included 2 cases of post-anesthesia syncope (associated with sacral cysts). The incidence of nausea was 2.2 %, and the total incidence of other adverse reactions, such as vomiting, urinary retention, bradycardia, anal discomfort, and dizziness, was less than 1 %.Ultrasound guided sacral anesthesia demonstrates significant advantages, including effective anesthesia, minimal impact on vital signs, rapid onset, prolonged maintenance, and a low incidence of adverse reactions. It is recommended for widespread application in intracavitary and/or interstitial brachytherapy for cervical cancer patients.